JANX PE Ratio & Valuation,Is JANX Overvalued

JANX Relative Valuation

JANX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, JANX is overvalued; if below, it's undervalued.

Historical Valuation

Janux Therapeutics Inc (JANX) is now in the Overvalued zone, suggesting that its current forward PS ratio of 820.64 is considered Overvalued compared with the five-year average of -15.49. The fair price of Janux Therapeutics Inc (JANX) is between 1.45 to 14.94 according to relative valuation methord. Compared to the current price of 15.30 USD , Janux Therapeutics Inc is Overvalued By 2.42%.

Relative Value

Fair Zone

1.45-14.94

Current Price：15.30

2.42%

Overvalued

-5.30

0.24

EV/EBITDA

Janux Therapeutics Inc. (JANX) has a current EV/EBITDA of 0.24. The 5-year average EV/EBITDA is -8.18. The thresholds are as follows: Strongly Undervalued below -25.49, Undervalued between -25.49 and -16.84, Fairly Valued between 0.47 and -16.84, Overvalued between 0.47 and 9.12, and Strongly Overvalued above 9.12. The current Forward EV/EBITDA of 0.24 falls within the Historic Trend Line -Fairly Valued range.

0.23

EV/EBIT

Janux Therapeutics Inc. (JANX) has a current EV/EBIT of 0.23. The 5-year average EV/EBIT is -8.53. The thresholds are as follows: Strongly Undervalued below -26.46, Undervalued between -26.46 and -17.50, Fairly Valued between 0.43 and -17.50, Overvalued between 0.43 and 9.39, and Strongly Overvalued above 9.39. The current Forward EV/EBIT of 0.23 falls within the Historic Trend Line -Fairly Valued range.

820.64

Janux Therapeutics Inc. (JANX) has a current PS of 820.64. The 5-year average PS is 508.42. The thresholds are as follows: Strongly Undervalued below -395.85, Undervalued between -395.85 and 56.29, Fairly Valued between 960.56 and 56.29, Overvalued between 960.56 and 1412.70, and Strongly Overvalued above 1412.70. The current Forward PS of 820.64 falls within the Historic Trend Line -Fairly Valued range.

-8.03

P/OCF

Janux Therapeutics Inc. (JANX) has a current P/OCF of -8.03. The 5-year average P/OCF is -14.28. The thresholds are as follows: Strongly Undervalued below -54.06, Undervalued between -54.06 and -34.17, Fairly Valued between 5.62 and -34.17, Overvalued between 5.62 and 25.51, and Strongly Overvalued above 25.51. The current Forward P/OCF of -8.03 falls within the Historic Trend Line -Fairly Valued range.

-4.68

P/FCF

Janux Therapeutics Inc. (JANX) has a current P/FCF of -4.68. The 5-year average P/FCF is -15.51. The thresholds are as follows: Strongly Undervalued below -40.58, Undervalued between -40.58 and -28.05, Fairly Valued between -2.97 and -28.05, Overvalued between -2.97 and 9.56, and Strongly Overvalued above 9.56. The current Forward P/FCF of -4.68 falls within the Historic Trend Line -Fairly Valued range.

Janux Therapeutics Inc (JANX) has a current Price-to-Book (P/B) ratio of 0.94. Compared to its 3-year average P/B ratio of 2.37 , the current P/B ratio is approximately -60.22% higher. Relative to its 5-year average P/B ratio of 2.20, the current P/B ratio is about -57.26% higher. Janux Therapeutics Inc (JANX) has a Forward Free Cash Flow (FCF) yield of approximately -7.76%. Compared to its 3-year average FCF yield of -5.97%, the current FCF yield is approximately 29.95% lower. Relative to its 5-year average FCF yield of -5.33% , the current FCF yield is about 45.67% lower.

0.94

P/B

Median3y

2.37

Median5y

2.20

-7.76

FCF Yield

Median3y

-5.97

Median5y

-5.33

Competitors Valuation Multiple

The average P/S ratio for JANX's competitors is 156.52, providing a benchmark for relative valuation. Janux Therapeutics Inc Corp (JANX) exhibits a P/S ratio of 820.64, which is 424.29% above the industry average. Given its robust revenue growth of 2177.90%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of JANX decreased by 71.42% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 439.00K to 10.00M.

The secondary factor is the Margin Expansion, contributed -96.20%to the performance.

Overall, the performance of JANX in the past 1 year is driven by Revenue Growth. Which is more sustainable.

2177.90%

439.00K → 10.00M

Revenue Growth

-96.20%

-6.39K → -243.13

Margin Expansion

-2153.12%

0.44 → -9.09

P/E Change

-71.42%

53.54 → 15.30

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Janux Therapeutics Inc (JANX) currently overvalued or undervalued?

What is Janux Therapeutics Inc (JANX) fair value?

JANX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Janux Therapeutics Inc (JANX) is between 1.45 to 14.94 according to relative valuation methord.

How does JANX's valuation metrics compare to the industry average?

What is the current P/B ratio for Janux Therapeutics Inc (JANX) as of Dec 15 2025?

As of Dec 15 2025, Janux Therapeutics Inc (JANX) has a P/B ratio of 0.94. This indicates that the market values JANX at 0.94 times its book value.

What is the current FCF Yield for Janux Therapeutics Inc (JANX) as of Dec 15 2025?

As of Dec 15 2025, Janux Therapeutics Inc (JANX) has a FCF Yield of -7.76%. This means that for every dollar of Janux Therapeutics Inc’s market capitalization, the company generates -7.76 cents in free cash flow.

What is the current Forward P/E ratio for Janux Therapeutics Inc (JANX) as of Dec 15 2025?

As of Dec 15 2025, Janux Therapeutics Inc (JANX) has a Forward P/E ratio of -5.30. This means the market is willing to pay $-5.30 for every dollar of Janux Therapeutics Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Janux Therapeutics Inc (JANX) as of Dec 15 2025?

As of Dec 15 2025, Janux Therapeutics Inc (JANX) has a Forward P/S ratio of 820.64. This means the market is valuing JANX at $820.64 for every dollar of expected revenue over the next 12 months.

JANX Valuation